Webinar
Development of a multiplex assay for prediction of immunotherapy response in metastatic melanoma patients
Watch NowMay 18 2022
On demand CEST
Online
Lunaphore webinar
Join Prof. Paolo Ascierto and Dr. Gabriele Madonna for an exclusive presentation during Melanoma Awareness Month.
At the end of the webinar, there will be a live Q&A session, giving the opportunity to ask your questions to our speakers.
Not available? Register anyway and access the webinar on demand.
May 18, 2022
Webinar
3:00 PM CEST
Online
Abstract:
Melanoma is the most aggressive among all skin cancers and is responsible for a high mortality rate. Combined immunotherapies have demonstrated greater efficacy in boosting the immune system of melanoma patients. However, the clinical decision on which combination to be used and which patients will benefit the most from it remains a challenge. Understanding the immune context of patients’ tumor and the identification of reliable biomarker readouts will assist clinicians in their decision. We developed a multiplex immunohistochemistry assay to profile the tumor microenvironment of metastatic melanoma patients who responded or did not to combined immunotherapy. We used LabSat®, an automated stainer based on Lunaphore’s microfluidic technology, to analyze the expression of PD-L1, CD8, and LAG-3. Our results provide first-time evidence of a different expression pattern of these markers between responder and non-responder melanoma patients.
Speakers
Prof. Paolo Ascierto
Director of the Unit of Melanoma
National Tumor Institute G. Pascale, Naples, Italy
Dr. Gabriele Madonna
Health Researcher
National Tumor Institute G. Pascale, Naples, Italy